Pantoprazole Sodium for Injection

This product is a proton pump inhibitor for gastric parietal cells. It is relatively stable under neutral and weakly acidic conditions and rapidly activated under strongly acidic conditions. Its pH-dependent activation characteristics make it more selective for H and K-ATPase. This product can specifically inhibit the H and K-ATPase on the secretory microtubules and tubular vesicles in the cytoplasm of the parietal cell apical membrane, causing irreversible inhibition of the enzyme, thereby effectively inhibiting the secretion of gastric acid. Since H and K-ATPase are the last process of acid secretion in parietal cells, this product has a strong acid-suppressing ability. It can not only non-competitively inhibit gastric acid secretion caused by gastrin, histamine, and choline, but also inhibit some basal gastric acid secretion that is not affected by choline or H2 receptor blockers. When used with other drugs, this product has the advantage of small drug interactions. This product is metabolized through the I system of the cytochrome P450 enzyme system in hepatocytes, and can also be metabolized through the II system. When used with other drugs that are metabolized by the P450 enzyme system, the metabolic pathway of this product can be carried out through the II enzyme system, which makes it less likely to have competitive effects on the drug-metabolizing enzyme system and reduce the interaction between drugs in the body. It has no mutagenic, carcinogenic and teratogenic effects.

The main ingredient of this product is pantoprazole sodium. Its chemical name is 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridyl)methyl]sulfinyl-1H-benzoimidazole sodium salt monohydrate. Molecular formula: C16H14F2N3NaO4S·H2O Molecular weight: 423.38

This product is white or off-white loose block or powder, and the special solvent is colorless clear liquid.

This product is suitable for duodenal ulcer, gastric ulcer, dosage form gastric mucosal lesions, combined gastric ulcer and other dosage forms of upper gastrointestinal ulcer with bleeding.

Usage: intravenous drip; Dosage: 40~80mg/time, 1~2 times/day.

Occasionally, dizziness, insomnia, drowsiness, nausea, diarrhea, constipation, rash and muscle pain may occur. Arrhythmia, elevated transaminases, changes in renal function and decreased granulocytes may occur when used in large doses.

It is contraindicated for those who are allergic to this product; it is contraindicated for pregnant and lactating women.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: It is contraindicated for pregnant and lactating women. Precautions for the elderly: There is no significant change in the pharmacokinetics (clearance, half-life, bioavailability) of pantoprazole in elderly patients, so the elderly do not need to change the dose.

Not yet clear.

Keep in airtight, light-proof place.

40mg

24 months.